Acute ST-Segment Elevation Myocardial Infarction Happened Within 2 Hours after First Dose of COVID-19 Vaccine

Jen Hung Huang; Jong Shiuan Yeh; Yung Kuo Lin; Ming Hsiung Hsieh

doi:10.6515/ACS.202205_38(3).20211128A

Acute ST-Segment Elevation Myocardial Infarction Happened Within 2 Hours after First Dose of COVID-19 Vaccine

Research output: Contribution to journal › Letter › peer-review

Abstract

Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute espiratory syndrome-coronavirus-2 (SARS-CoV-2). The Oxford-AstraZeneca COVID-19 vaccine is based on an adenovirus vector and has been extensively used to prevent the COVID-19 infection or complications. Severe thrombotic adverse reactions caused by the AstraZeneca COVID-19 vaccine have been reported in several countries.1 Acute myocardial infarction (AMI) is an emergent cardiovascular disease and occurs mostly due to thrombus obstruction of the coronary artery caused by a rupture of atherosclerotic plaques. Herein, we report a case of a 60-year-old man with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) after receiving his first dose of the AstraZeneca vaccine.

Original language	English
Pages (from-to)	417-420
Number of pages	4
Journal	Acta Cardiologica Sinica
Volume	38
Issue number	3
DOIs	https://doi.org/10.6515/ACS.202205_38(3).20211128A
Publication status	Published - May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.6515/ACS.202205_38(3).20211128A

Cite this

@article{31533bb059034f66be01c463f7c76ea2,

title = "Acute ST-Segment Elevation Myocardial Infarction Happened Within 2 Hours after First Dose of COVID-19 Vaccine",

abstract = "Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute espiratory syndrome-coronavirus-2 (SARS-CoV-2). The Oxford-AstraZeneca COVID-19 vaccine is based on an adenovirus vector and has been extensively used to prevent the COVID-19 infection or complications. Severe thrombotic adverse reactions caused by the AstraZeneca COVID-19 vaccine have been reported in several countries.1 Acute myocardial infarction (AMI) is an emergent cardiovascular disease and occurs mostly due to thrombus obstruction of the coronary artery caused by a rupture of atherosclerotic plaques. Herein, we report a case of a 60-year-old man with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) after receiving his first dose of the AstraZeneca vaccine.",

author = "Huang, \{Jen Hung\} and Yeh, \{Jong Shiuan\} and Lin, \{Yung Kuo\} and Hsieh, \{Ming Hsiung\}",

year = "2022",

month = may,

doi = "10.6515/ACS.202205\_38(3).20211128A",

language = "English",

volume = "38",

pages = "417--420",

journal = "Acta Cardiologica Sinica",

issn = "1011-6842",

publisher = "Republic of China Society of Cardiology",

number = "3",

}

TY - JOUR

T1 - Acute ST-Segment Elevation Myocardial Infarction Happened Within 2 Hours after First Dose of COVID-19 Vaccine

AU - Huang, Jen Hung

AU - Yeh, Jong Shiuan

AU - Lin, Yung Kuo

AU - Hsieh, Ming Hsiung

PY - 2022/5

Y1 - 2022/5

N2 - Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute espiratory syndrome-coronavirus-2 (SARS-CoV-2). The Oxford-AstraZeneca COVID-19 vaccine is based on an adenovirus vector and has been extensively used to prevent the COVID-19 infection or complications. Severe thrombotic adverse reactions caused by the AstraZeneca COVID-19 vaccine have been reported in several countries.1 Acute myocardial infarction (AMI) is an emergent cardiovascular disease and occurs mostly due to thrombus obstruction of the coronary artery caused by a rupture of atherosclerotic plaques. Herein, we report a case of a 60-year-old man with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) after receiving his first dose of the AstraZeneca vaccine.

AB - Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute espiratory syndrome-coronavirus-2 (SARS-CoV-2). The Oxford-AstraZeneca COVID-19 vaccine is based on an adenovirus vector and has been extensively used to prevent the COVID-19 infection or complications. Severe thrombotic adverse reactions caused by the AstraZeneca COVID-19 vaccine have been reported in several countries.1 Acute myocardial infarction (AMI) is an emergent cardiovascular disease and occurs mostly due to thrombus obstruction of the coronary artery caused by a rupture of atherosclerotic plaques. Herein, we report a case of a 60-year-old man with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) after receiving his first dose of the AstraZeneca vaccine.

UR - https://www.scopus.com/pages/publications/85135595235

UR - https://www.scopus.com/pages/publications/85135595235#tab=citedBy

U2 - 10.6515/ACS.202205_38(3).20211128A

DO - 10.6515/ACS.202205_38(3).20211128A

M3 - Letter

AN - SCOPUS:85135595235

SN - 1011-6842

VL - 38

SP - 417

EP - 420

JO - Acta Cardiologica Sinica

JF - Acta Cardiologica Sinica

IS - 3

ER -

Acute ST-Segment Elevation Myocardial Infarction Happened Within 2 Hours after First Dose of COVID-19 Vaccine

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this